Evidence map›Paper›PMID 38948530›Full record

ReviewCancer innovation2024

Postmastectomy radiotherapy in breast reconstruction: Current controversies and trends.

Honghong Zhang, Dandan Song, Liangxi Xie, Ning Zhan, Wenjia Xie, Jianming Zhang

Abstract readReview
In one paragraph

Review in Cancer innovation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Honghong ZhangDepartment of Radiation Oncology, Xiang'an Hospital of Xiamen University, Cancer Research Center, School of Medicine Xiamen University, Xiang'an Xiamen Fujian China.ORCID 0000-0002-3893-5763
Dandan SongDepartment of Radiation Oncology, Xiang'an Hospital of Xiamen University, Cancer Research Center, School of Medicine Xiamen University, Xiang'an Xiamen Fujian China.ORCID 0009-0001-2112-9765
Liangxi XieDepartment of Radiation Oncology, Xiang'an Hospital of Xiamen University, Cancer Research Center, School of Medicine Xiamen University, Xiang'an Xiamen Fujian China.
Ning ZhanDepartment of Radiation Oncology, Xiang'an Hospital of Xiamen University, Cancer Research Center, School of Medicine Xiamen University, Xiang'an Xiamen Fujian China.
Wenjia XieDepartment of Radiation Oncology, Xiang'an Hospital of Xiamen University, Cancer Research Center, School of Medicine Xiamen University, Xiang'an Xiamen Fujian China.
Jianming ZhangFujian Provincial Key Laboratory of Intelligent Identification and Control of Complex Dynamic System, Quanzhou Institute of Equipment Manufacturing, Haixi Institutes Chinese Academy of Sciences Quanzhou Fujian China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common cancer among women worldwide. Postmastectomy radiotherapy (PMRT) is an essential component of combined therapy for early-stage, high-risk breast cancer. Breast reconstruction (BR) is often considered for patients with breast cancer who have undergone mastectomy. There has been a considerable amount of discussion about the optimal approach to combining PMRT with BR in the treatment of breast cancer. PMRT may increase the risk of complications and prevent good aesthetic results after BR, while BR may increase the complexity of PMRT and the radiation dose to surrounding normal tissues. The purpose of this review is to give a broad overview and summary of the current controversies and trends in PMRT and BR in the context of the most recent literature available.

Indexed as

breast reconstructionpostmastectomy radiotherapyradiotherapy techniques

Identifiers

PMID38948530
PMCPMC11212305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.